After the successful launch of Tabuk’s first product Brospect® to the hospital market in Turkey in June 2007, Brospect® “Ceftazidime Pentahydrate” won 48% of hospital tenders during the first half of 2008.
Tabuk gained registration approvals for Diclofenac Potassium tablets & Cetrizine Dihydochloride. These new introductions shall trigger the 1st expansion phase of Tabuk Turkey to successfully launch the new products to the open care market during Q4/2008.